143 related articles for article (PubMed ID: 35257539)
1. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma.
Valdesoiro-Navarrete L; León ME; Rodríguez M; Indiveri M; Ayats R; Larramona H; González MG; de la Cruz ÒA; García MB
Allergol Immunopathol (Madr); 2022; 50(2):1-6. PubMed ID: 35257539
[TBL] [Abstract][Full Text] [Related]
2. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
3. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
Carrier C; Demoly P; Caimmi D
Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
[TBL] [Abstract][Full Text] [Related]
4. Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
Zhang YY; Zhang M; Zhang JQ; Li QQ; Lu MP; Cheng L
Int Forum Allergy Rhinol; 2024 Apr; 14(4):794-806. PubMed ID: 37715592
[TBL] [Abstract][Full Text] [Related]
5. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.
Har D; Lee MJ
Allergy Asthma Proc; 2019 Jan; 40(1):35-40. PubMed ID: 30582494
[No Abstract] [Full Text] [Related]
6. Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
De Filippo M; Votto M; Caminiti L; Carella F; Castro G; Landi M; Olcese R; Panasiti I; Vernich M; Barberi S; Ciprandi G; Marseglia GL
Allergol Immunopathol (Madr); 2022; 50(6):47-52. PubMed ID: 36335444
[TBL] [Abstract][Full Text] [Related]
7. Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma.
Bozek A; Rogala B; Miodonska M; Canonica GW
J Asthma; 2024 Jun; 61(6):532-538. PubMed ID: 38064236
[TBL] [Abstract][Full Text] [Related]
8. 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.
Folqué MM; Lozano J; Riggioni C; Piquer M; Álvaro M; Machinena A; Giner MT; Domínguez O; Jiménez-Feijoo RM; Dias da Costa M; Plaza AM
Allergol Immunopathol (Madr); 2019; 47(4):336-341. PubMed ID: 30509559
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
10. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
11. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment.
Rodríguez Del Río P; Vidal C; Just J; Tabar AI; Sanchez-Machin I; Eberle P; Borja J; Bubel P; Pfaar O; Demoly P; Calderón MA
Pediatr Allergy Immunol; 2017 Feb; 28(1):60-70. PubMed ID: 27637414
[TBL] [Abstract][Full Text] [Related]
12. Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance.
Nakamura N; Kashitani Y; Yoshisue H; Nagasaki M; Sasajima T
Allergol Int; 2021 Jul; 70(3):319-326. PubMed ID: 33526351
[TBL] [Abstract][Full Text] [Related]
13. Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study.
Fiocchi A; Artesani MC; Riccardi C; Mennini M; Pecora V; Fierro V; Calandrelli V; Dahdah L; Valluzzi RL
J Allergy Clin Immunol Pract; 2019; 7(6):1901-1909.e5. PubMed ID: 30797778
[TBL] [Abstract][Full Text] [Related]
14. Allergen immunotherapy and asthma: efficacy, safety, and other considerations.
Cox L
Allergy Asthma Proc; 2008; 29(6):580-9. PubMed ID: 19173785
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
[No Abstract] [Full Text] [Related]
16. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
Morales-Múnera O; Pedraza Á; Niño-Serna L
Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
18. Real-World Safety and Effectiveness Evidence of a Microcrystalline Tyrosine-Associated Mite Allergoid in Children and Adolescents with Allergic Rhinitis.
Anna SC; Zulay M AS; Ignacio GN; Sofia L; Juan A MT; Maria D M; Ramón N; Mercedes R; Anna B; Carla TB; José L J
Allergol Immunopathol (Madr); 2021; 49(4):98-108. PubMed ID: 34224224
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
